Valneva (NASDAQ:VALN) Price Target Cut to $15.00 by Analysts at Guggenheim

Valneva (NASDAQ:VALN - Get Free Report) had its price target decreased by Guggenheim from $17.00 to $15.00 in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective indicates a potential upside of 106.61% from the company's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Friday, March 21st.

Valneva Stock Up 0.1 %

Shares of NASDAQ:VALN opened at $7.26 on Monday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $589.95 million, a price-to-earnings ratio of -55.85 and a beta of 1.93. The company has a 50 day moving average of $6.63 and a two-hundred day moving average of $5.61.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million during the quarter, compared to the consensus estimate of $55.64 million. As a group, analysts forecast that Valneva will post 0.13 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in Valneva SE (NASDAQ:VALN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 19,244 shares of the company's stock, valued at approximately $84,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.